Reuters logo
4 个月前
BRIEF-Crispr and Casebia announce commercial license agreement with Maxcyte
2017年3月14日 / 中午12点03分 / 4 个月前

BRIEF-Crispr and Casebia announce commercial license agreement with Maxcyte

1 分钟阅读

March 14 (Reuters) - Crispr Therapeutics Ag

* Crispr Therapeutics and Casebia Therapeutics announce commercial license agreement with Maxcyte

* Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments

* Says commercial license builds on an existing research and clinical licensing agreement for select disease areas

* Crispr, Casebia will obtain non-exclusive commercial-use rights to Maxcyte's cell engineering platform to develop crispr/CAS9-based therapies for SCID Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below